VEGFR-TKI treatment for radiation-induced brain injury after gamma knife radiosurgery for brain metastases from renal cell carcinomas

被引:1
作者
Noda, Ryuichi [1 ,2 ,4 ]
Akabane, Atsuya [1 ]
Kawashima, Mariko [1 ]
Uchino, Keita [3 ]
Tsunoda, Sho [2 ]
Segawa, Masafumi [2 ]
Inoue, Tomohiro [2 ]
机构
[1] Gamma Knife Ctr, NTT Med Ctr Tokyo, Tokyo, Japan
[2] NTT Med Ctr Tokyo, Dept Neurosurg, Tokyo, Japan
[3] NTT Med Ctr Tokyo, Dept Med Oncol, Tokyo, Japan
[4] NTT Med Ctr Tokyo, Higashi Gotanda, Shinagawa-ku, Tokyo, Japan
关键词
vascular endothelial growth factor receptor tyrosine kinase inhibitor; renal cell carcinoma; brain metastasis; gamma knife radiosurgery; radiation-induced brain injury; radiation necrosis; STEREOTACTIC RADIOSURGERY; BEVACIZUMAB; NECROSIS; SURGERY; EDEMA; INHIBITORS; SUNITINIB; EFFICACY; OUTCOMES; SAFETY;
D O I
10.1093/jjco/hyac197
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective Antiangiogenic vascular endothelial growth factor receptor tyrosine kinase inhibitors play an essential role in systemic therapy for renal cell carcinoma. Given the anti-edematous effect of bevacizumab, an antiangiogenic antibody targeting vascular endothelial growth factor, vascular endothelial growth factor receptor tyrosine kinase inhibitors should exert therapeutic effects on radiation-induced brain injury after stereotactic radiosurgery. This preliminary study aimed to investigate the therapeutic effect of vascular endothelial growth factor receptor tyrosine kinase inhibitor against radiation-induced brain injury. Methods Magnetic resonance images for six patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors who were diagnosed with radiation-induced brain injury following gamma knife radiosurgery were retrospectively reviewed. Results The median brain edema volume and tumour mass volume in the pre-tyrosine kinase inhibitor period were 57.6 mL (range: 39.4-188.2) and 3.2 mL (range: 1.0-4.6), respectively. Axitinib, pazopanib (followed by cabozantinib) and sunitinib were administered in four, one and one cases, respectively. The median brain edema volume and tumour mass volume in the post-tyrosine kinase inhibitor period were 4.8 mL (range: 1.5-27.8) and 1.6 mL (range: 0.4-3.6), respectively. The median rates of reduction in brain edema volume and tumour mass volume were 90.8% (range: 51.9-97.6%) and 57.2% (range: 20.0-68.6%), respectively. The post-tyrosine kinase inhibitor values for brain edema volume (P = 0.027) and tumour mass volume (P = 0.008) were significantly lower than the pre-tyrosine kinase inhibitor values. Changes in volume were correlated with tyrosine kinase inhibitor use. Conclusion This study is the first to demonstrate the therapeutic effects of vascular endothelial growth factor receptor tyrosine kinase inhibitors on radiation-induced brain injury in patients with brain metastases from renal cell carcinoma treated via gamma knife radiosurgery. Vascular endothelial growth factor receptor tyrosine kinase inhibitors had therapeutic effects on radiation-induced brain injury in patients with brain metastases from renal cell carcinoma treated with gamma knife radiosurgery.
引用
收藏
页码:355 / 364
页数:10
相关论文
共 49 条
[1]   The role of VEGF receptor inhibitors in preventing cerebral radiation necrosis: a retrospective cohort study [J].
Alnahhas, Iyad ;
Rayi, Appaji ;
Palmer, Joshua D. ;
Raval, Raju ;
Folefac, Edmund ;
Ong, Shirley ;
Giglio, Pierre ;
Puduvalli, Vinay .
NEURO-ONCOLOGY PRACTICE, 2021, 8 (01) :75-80
[2]   Efficacy of bevacizumab in the treatment of refractory brain edema of metastatic tumors from different sources [J].
Bai, Xuexue ;
Zhang, Yuan ;
Ding, Weilong ;
Wang, Shiyong .
NEUROLOGICAL RESEARCH, 2021, 43 (12) :955-960
[3]   Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation [J].
Bamias, Aristotle ;
Escudier, Bernard ;
Sternberg, Cora N. ;
Zagouri, Flora ;
Dellis, Athanasios ;
Djavan, Bob ;
Tzannis, Kimon ;
Kontovinis, Loukas ;
Stravodimos, Konstantinos ;
Papatsoris, Athanasios ;
Mitropoulos, Dionysios ;
Deliveliotis, Charalampos ;
Dimopoulos, Meletios-Athanasios ;
Constantinides, Constantine A. .
ONCOLOGIST, 2017, 22 (06) :667-679
[4]   Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery [J].
Boothe, Dustin ;
Young, Robert ;
Yamada, Yoshiya ;
Prager, Alisa ;
Chan, Timothy ;
Beal, Kathryn .
NEURO-ONCOLOGY, 2013, 15 (09) :1257-1263
[5]  
Brown PD, 2008, NEUROSURGERY, V62, P790, DOI [10.1227/01.neu.0000316283.45242.e1, 10.1227/01.NEU.0000023713.44940.20]
[6]   The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma [J].
Calvo, Emiliano ;
Porta, Camillio ;
Grunwald, Viktor ;
Escudier, Bernard .
ONCOLOGIST, 2019, 24 (03) :338-348
[7]   A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases [J].
Chevreau, Christine ;
Ravaud, Alain ;
Escudier, Bernard ;
Amela, Eric ;
Delva, Remy ;
Rolland, Frederic ;
Tosi, Diego ;
Oudard, Stephane ;
Blanc, Ellen ;
Ferlay, Celine ;
Negrier, Sylvie .
CLINICAL GENITOURINARY CANCER, 2014, 12 (01) :50-54
[8]   Pathophysiology of Cerebral Edema-A Comprehensive Review [J].
Dalby, Tara ;
Wohl, Elyana ;
Dinsmore, Michael ;
Unger, Zoe ;
Chowdhury, Tumul ;
Venkatraghavan, Lakshmikumar .
JOURNAL OF NEUROANAESTHESIOLOGY AND CRITICAL CARE, 2021, 08 (03) :163-172
[9]   BRAIN METASTASES IN PATIENTS WITH RENAL-CELL CARCINOMA - PROGNOSIS AND TREATMENT [J].
DECKER, DA ;
DECKER, VL ;
HERSKOVIC, A ;
CUMMINGS, GD .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (03) :169-173
[10]  
Delishaj Durim, 2017, J Clin Med Res, V9, P273, DOI 10.14740/jocmr2936e